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Abstract
Myelodysplastic syndromes (MDS) are the most common adult myeloid blood cancers in
the US. Patients have increased apoptosis in their bone marrow cells leading to low periph-
eral blood counts. The full complement of gene mutations that contribute to increased apo-
ptosis in MDS remains unknown. Up to 25% of MDS patients harbor and acquired interstitial
deletion on the long arm of chromosome 5 [del(5q)], creating haploinsufficiency for a large
set of genes including HSPA9. Knockdown of HSPA9 in primary human CD34+ hematopoi-
etic progenitor cells significantly inhibits growth and increases apoptosis. We show here that
HSPA9 knockdown is associated with increased TP53 expression and activity, resulting in
increased expression of target genes BAX and p21. HSPA9 protein interacts with TP53 in
CD34+ cells and knockdown of HSPA9 increases nuclear TP53 levels, providing a possible
mechanism for regulation of TP53 by HSPA9 haploinsufficiency in hematopoietic cells. Con-
current knockdown of TP53 and HSPA9 rescued the increased apoptosis observed in CD34
+ cells following knockdown of HSPA9. Reduction of HSPA9 below 50% results in severe
inhibition of cell growth, suggesting that del(5q) cells may be preferentially sensitive to fur-
ther reductions of HSPA9 below 50%, thus providing a genetic vulnerability to del(5q) cells.
Treatment of bone marrow cells with MKT-077, an HSPA9 inhibitor, induced apoptosis in a
higher percentage of cells from MDS patients with del(5q) compared to non-del(5q) MDS
patients and normal donor cells. Collectively, these findings indicate that reduced levels of
HSPA9 may contribute to TP53 activation and increased apoptosis observed in del(5q)-
associated MDS.
Introduction
Myelodysplastic syndromes (MDS) are a heterogeneous group of blood cancers characterized
by abnormal hematopoietic cell maturation, increased apoptosis of bone marrow cells, and
peripheral blood cytopenias. Low blood counts result in morbidity and mortality due to
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bleeding and infection. A fraction of patients will progress from MDS to secondary acute mye-
loid leukemia (AML), characterized by a reduction in apoptosis, the etiology of which is
incompletely understood. Up to 25% of MDS patients acquire an interstitial deletion on chro-
mosome 5q, also known as del(5q). Two distinct commonly deleted regions (CDR) on the
long arm of chromosome 5 have been identified in patients with MDS and AML. The distal
CDR spans chromosome 5q33.1 (148.6–151.1 Mb) and contains 44 genes, including RPS14.
[1–3] The proximal CDR spans chromosome 5q31.2 (136.3–138.6 Mb) and contains 30 genes
including HSPA9, and is associated with patients that progress from MDS to secondary AML,
or have therapy–related MDS and AML.[2–4] Our group, and others, hypothesize that hap-
loinsufficiency of genes on del(5q) contribute to increased apoptosis and peripheral blood
cytopenias observed in MDS.
The human HSPA9 gene is located on chromosome 5q31.2 and encodes for one of the heat
shock protein 70 family members, also known as mortalin/mthsp70/PBP74/GRP75. HSPA9 is
localized in the mitochondria, endoplasmic reticulum, plasma membrane, cytoplasmic vesicles
and cytosol.[5] As a molecular chaperone, HSPA9 interacts with other proteins and functions
in regulating cellular stress response, cell proliferation and apoptosis.[6] The role of HSPA9 in
hematopoiesis has been studied in multiple models. Knockdown of HSPA9 in primary human
CD34+ hematopoietic progenitors inhibits erythroid cell maturation and increases apoptosis.
[7] Zebrafish with a homozygous point mutation in Hspa9 present phenotypically with a vari-
ety of abnormalities including severe anemia, defects in erythroid differentiation and elevated
apoptosis.[8] Knockdown of Hspa9 in a mouse bone marrow transduction transplantation
model showed reduction in hematopoietic stem and progenitor cells [9,10] and heterozygous
deletion of Hspa9 in mice alters B-cell lymphopoiesis.[11] Collectively, these studies revealed
important functions of HSPA9 in hematopoiesis, suggesting it may contribute to the increased
apoptosis observed in MDS.
Increased apoptosis in del(5q) MDS cells is associated with elevated levels of TP53 in ery-
throid cells.[12,13] There is evidence that haploinsufficiency of genes on del(5q) contribute
to increased TP53 and apoptosis. Reduced levels of RPS14, a 5q33.1 gene, increases apoptosis
of human progenitor cells via increased TP53 levels.[12] We hypothesize that multiple genes
on del(5q) may contribute to apoptosis through TP53 activation. Prior studies in non-
hematopoietic cells show HSPA9 binds to the cytoplasmic sequestration domain of TP53
and knockdown of HSPA9 results in relocation of TP53 from the cytoplasm to the nucleus.
[5,14–16] It is not known whether reduced expression of HSPA9 in primary human hemato-
poietic cells results in activation of TP53 and the induction of apoptosis. In this study, we
examine the relationship between the levels of HSPA9 and TP53 in human CD34+ hemato-




Granulocyte colony-stimulating factor (G-CSF) mobilized peripheral blood hematopoietic
progenitor cells (CD34+) were obtained from Fred Hutchinson Cancer Research Center (Seat-
tle, WA, USA) (purity of CD34+ cells were higher than 90%). MDS bone marrow samples
were collected on a protocol approved by the Human Research Protection Office at Washing-
ton University. The study was carried out in accordance with the Declaration of Helsinki and
amendments and informed written consent was obtained from all subjects prior to enrollment.
MKT-077 was obtained from Sigma-Aldrich (St Louis, MO, USA).
HSPA9 knockdown induces apoptosis
PLOS ONE | DOI:10.1371/journal.pone.0170470 February 8, 2017 2 / 18
Scholar Award (MJW). The Siteman Flow
Cytometry Core is supported in part by an NCI
Cancer Center Support Grant (#P30 CA91842).
Additional technical assistance was provided by the
Hope Center Viral Vectors Core, which is supported
by a Neuroscience Blueprint Interdisciplinary
Center Core Award (P30NS057105). The Fred
Hutchinson Cancer Research Center that supplied
CD34+ cells is supported by a Cooperative Centers
of Excellence in Hematology grant from NIH
(DK106829). The funders had no role in study
design, data collection and analysis, decision to
publish, or preparation of the manuscript.
Competing interests: The authors have declared
that no competing interests exist.
Lentiviral shRNA vectors and production
The production of pLK0.1 lentiviral shRNAs has been described previously.[10] shRNA
sequences are listed in S1 Table.
Lentiviral shRNA vector transduction and culture
Transduction of lentiviral shRNA (S1 Table) into human CD34+ cells and associated culture
conditions have been described previously.[10] Briefly, CD34+ progenitor cells were primed
in X-VIVO 15 medium (Lonza, Walkersville) containing human cytokines (50 ng/mL of stem-
cell factor [SCF], 50 ng/mL of Fms-related tyrosine kinase 3 ligand [FLT3-ligand], 50 ng/mL
of thrombopoietin [TPO], and 50 ng/mL of interleukin 3 [IL-3] [PeproTech]) with L-gluta-
mine (Thermo Fisher Scientific) overnight before lentiviral transduction. Cells were spinocu-
lated in the presence of polybrene (5 μg/mL) and incubated overnight at 37˚C in 5% CO2.
Cells were washed and incubated in erythroid differentiation media containing serum-free
expansion medium (StemCell Technologies) with 25 ng/mL of SCF, 10 ng/mL of IL3, 10
ng/mL of IL6, 0.5 units of erythropoietin (EPO), 100 U/mL of penicillin/streptomycin (P/S),
and L-glutamine for 7 days. All cytokines were obtained from Peprotech.
Western blotting
Cell lysates were prepared in radioimmunoprecipitation assay (RIPA) buffer as described pre-
viously.[10] The following antibodies were used: TP53 (SC-126; Santa Cruz Biotechnology),
Bax (554104; BD Pharmagen), HSPA9 (MA3-028; Affinity BioReagents), β-actin (A5441;
Sigma-Aldrich), and lamin B1 (ab16048; Abcam). Densitometry was performed using ImageJ
(http://imagej.nih.gov/ij/) (S2 Table).
Cytosol and nuclear fraction isolation
The nuclear and cytoplasmic fractions of CD34+ cells were isolated using a previously pub-
lished protocol.[17] 1x107 CD34+ cells were harvested by centrifuging at 500g for 5 minutes
and then washed with PBS. The cell pellet was resuspended with 1 ml of ice-cold HLB buffer
(10 mM Tris [pH 7.5], 10 mM NaCl, 3 mM MgCl2, 0.3% [vol/vol] NP-40 and 10% [vol/vol]
glycerol) and incubated on ice for 10 minutes. The cell suspension was then centrifuged at
800g for 8 minutes at 4˚C. The supernatant contains the cytosol fraction. The nuclear pellet
was washed four times by HLB buffer and centrifuged at 200g for 2 minutes at 4˚C. The
nuclear pellet was then resuspended in 0.5 ml ice-cold NLB (20 mM Tris [pH 7.5], 150 mM
KCl, 3 mM MgCl2, 0.3% [vol/vol] NP-40 and 10% [vol/vol] glycerol). The nuclei were soni-
cated three times at 20% power for 15 seconds in an ice bath with 2 minutes of cooling between
each sonication. The sonicated nuclei were then centrifuged at 16,000g for 15 minutes at 4˚C
and the supernatant was collected. The cytosol and nuclear fractions were used for Western
blotting. Beta-actin and lamin B were used to measure the purity of cytosol and nuclear frac-
tions, respectively.
RT-PCR
Cells were harvested by centrifugation at 1500 g for 5 minutes at 4˚C, resuspended in 250 μL
1X PBS, then lysed by adding 750 μL Trizol LS reagent (Invitrogen). RNA was then isolated
following the manufacturer’s protocol. RNA was resuspended in 30 μL of RNase-free water
and the RNA concentration was measured using a NanoDrop 2000 spectrophotometer (Ther-
moFisher scientific, Wilmington, DE, USA). The TURBO DNA-free kit (Thermo Fisher Scien-
tific) was used to remove DNA contamination in the RNA samples. The first-strand cDNA
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was synthesized using the SuperScript III first-strand synthesis system. FAM-MGB primer/
probe mixes for TP53 (Hs01034249_m1), HSPA9 (Hs00945576_g1), GAPDH
(Hs02758991_g1), BAX (Hs00180269_m1) and p21 (Hs00355782_m1) were used for RT-PCR
TaqMan gene expression assays (Applied Biosystems). All RT-PCR reactions were performed
in duplicate with no-RT control and water control on a StepOne Plus Real time PCR System
(Applied Biosystems). Individual cDNA samples were normalized according to their levels of
GAPDH and the relative standard curve method was used for analysis.
Luciferase reporter assay
CD34+ cells were transduced with shGFP, sh433 (shHSPA9 #2) and sh960 (shHSPA9 #1) and
cultured for 5 days as previously reported.[10] PG13 and renilla plasmids (a gift from Dr.
Zaika) were electroporated into the CD34+ cells using Amaxa human CD34+ cell nucleofector
(program U-008) following the manufacturer’s protocol (Lonza, Allendale, NJ).[18] Two days
after electroporation, luciferase and renilla activity were measured using the Renilla luciferase
assay system from Promega (Madison, WI) following manufacturer’s protocol. Plates were
read using AD/LD analysis software from Beckman Coulter LD40 (Pasadena, CA).
Flow cytometry
Flow cytometry was used to measure the apoptotic cells using Annexin V as previously
described.[10] Intracellular flow cytometry to measure TP53 has been described previously.
[12] The following antibodies were used: anti-CD71 (FITC, 11-0719-42, ebioscience), anti-gly-
cophorin A (PE, 12-9987-80, ebioscience), anti-TP53 (Alexa647, #2533S, cell signaling) and
Annexin V (556421, BD Pharmingen).
Gene set enrichment analysis
CD34+/CD71- cells were isolated using Fluorescence-activated cell sorting (FACS) from 4
independent cultures of CD34+ cells differentiated in erythroid cytokines for 5 days following
transduction with sh433 (shHSPA9 #2) or shLUC. We isolated RNA as described above and
performed Affymetrix Gene 1.0 ST mRNA arrays. Gene Set Enrichment Analysis (GSEA) was
performed using a set of well-annotated TP53-target genes and p21-inhibited genes.[19] The
Affymetrix data has been deposited in GEO (GSE78164).
Immunoprecipitation
The immunoprecipitation method has been described previously.[20] Briefly, 2x107 cells were
harvested after 5 days in erythroid culture and lysed in 1 ml 1X RIPA buffer on ice for 30 min-
utes with sonication. The lysates were centrifuged at 16,000g for 10 minutes and the superna-
tant was collected and used in the immunoprecipitation assay. 50 μL of TP53 antibody-
conjugated agarose beads (sc-126 AC, Santa Cruz) or mouse IgG−agarose beads (A0919,
Sigma) were washed three times with 1X RIPA buffer followed by centrifugation at 100g for 3
minutes at 4˚C and the supernatant was discarded. The lysates were then incubated with the
TP53 antibody-conjugated agarose beads or mouse IgG−agarose beads for 1 hour at room
temperature with rotation. After incubation, the mixture was centrifuged at 100g for 3 minutes
at 4˚C and the supernatant was used for Western blotting analysis. The immunoprecipitate
was washed three times with 0.9% saline. After washing, the immunoprecipitated mixture was
eluted with 200 μL of 0.1M glycine. All fractions at different stages were collected and used for
Western blotting assay.
HSPA9 knockdown induces apoptosis
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Immunofluorescence and fluorescence digital imaging microscopy
Cells were washed 2X with PBS, and transferred by cytospin to Superfrost Plus Microscope
Slides (Fisher). The cells were then fixed with 0.4% paraformaldehyde (diluted in PBS) for
20 minutes at room temperature. The cells were washed 3X with PBS, and permeabilized
with 0.3% Triton X-100 (diluted in PBS) at 4˚C overnight. The cells were then washed 3X
with 0.1% Tween 20 in PBS (PBST), and incubated in 10% donkey serum in PBST (blocking
buffer) for 1 hour. After blocking, cells were incubated with monoclonal TP53 antibody
(DO-1, Santa Cruz Biotechnology; diluted 1:200 in blocking buffer) overnight. The cells
were washed 3X with PBST, and secondary staining was performed by incubating with
Alexa Fluor594-conjugated goat polyclonal antibody to mouse IgG (ab150120, Abcam;
diluted 1:200 in blocking buffer) for 2 hours at room temperature. The cells were then
washed 3X with PBST. Mounting reagent, Prolong Gold Antifade Reagent with DAPI
(P36931, Invitrogen) was then applied onto the cell surface, covered with a coverslip, and
sealed. Fluorescent imaging was then performed through a 40X objective, using a Zeiss LSM
700 microscope.
Statistics
Statistical significance of the data between two groups was analyzed by the Student t-test (Prism
5). Statistical significance of the data with more than two groups was analyzed by one-way
ANOVA with a Tukey post-test (Prism 5). Significance levels were set at p<0.05 (labelled ),
p<0.01 (labelled ), and p<0.001 (labelled ).
Results
Knockdown of HSPA9 increases TP53 levels and activity in primary
human CD34+ progenitor cells
We used primary human CD34+ hematopoietic progenitor cells grown in unilineage ery-
throid expansion media to explore the mechanism of increased apoptosis observed in ery-
throid cells from del(5q) MDS patients. In order to test the effects of HSPA9 knockdown in
human CD34+ hematopoietic progenitor cells, we utilized two previously reported short
hairpin RNAs targeting the human HSPA9 gene (sh433 and sh960).[10] sh433 and sh960
previously reduced the HSPA9 protein level to approximately 50% and 20%,[10] respectively
(and in Fig 1A), and mRNA level to 64%±4% (p<0.01) and 39% ± 8% (p<0.01), respectively,
compared to control shGFP (S1A Fig). Consistent with previous results, knockdown of
HSPA9 inhibits cell growth and increased apoptosis of CD34+ cells cultured in erythroid
media (Fig 1B and 1C).[10] To identify potential genes contributing to this phenotype, we
flow sorted CD34+/CD71- cells from 4 independent cultures, 5 days after transduction with
shLUC (control) and sh433 (shHSPA9 #2 in prior study).[10] sh433 was chosen to approxi-
mate haploinsufficient levels of HSPA9 mRNA observed in MDS samples with del(5q) com-
pared to non-del(5q) samples.[4] We isolated CD34+/CD71- cells in order to study
progenitor cells. We chose day 5 because CD34+/CD71- cells had similar cell cycle and apo-
ptotic profiles at that time (data not shown), allowing us to identify dysregulated genes that
precede changes in cell cycle and levels of apoptosis, and not as a consequence of these pro-
cesses. We isolated RNA and performed Affymetrix Gene 1.0 ST mRNA arrays. HSPA9
mRNA was reduced by ~50% in the knockdown samples on the arrays (expression level of
sh433 versus shLUC = 1684 ± 18.24 versus 3615 ± 125.8 [arbitrary units], respectively,
p<0.001, N = 4). Unsupervised clustering analysis did not consistently segregate the sam-
ples, indicating that massive transcriptional changes did not occur at this time point, as
HSPA9 knockdown induces apoptosis
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Fig 1. Knockdown of HSPA9 increases TP53 expression and activity in CD34+ cells. (A) Representative immunoblot of HSPA9
and TP53 protein in CD34+ cells transduced with shRNAs targeting a control gene (GFP) or HSPA9 after 7 days in erythroid culture
conditions. (B) Transduced cells were seeded at equal concentrations in erythroid culture media and the total number of cells was
counted daily in the presence of puromycin selection. The fold change in cell counts was calculated relative to the number of cells on
day 1 (n = 3 independent replicates for each shRNA). (C) Quantification of Annexin V+ cells (a surrogate for apoptosis) following
knockdown of HSPA9 in CD34+ cells (n = 3 for each shRNA). (D) Gene Set Enrichment Analysis (GSEA) enrichment score plot for
26 annotated TP53-induced genes. Individual genes in the gene set are represented by a black vertical bar in the middle of the plot.
(E) TP53 luciferase reporter assay showed a dose-dependent increase in TP53 activity following HSPA9 knockdown (n = 3). LUC,
luciferase. * p<0.05, ** p<0.01, *** p<0.001.
doi:10.1371/journal.pone.0170470.g001
HSPA9 knockdown induces apoptosis
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expected based on the experimental design. However, using supervised approaches (Gene
Set Enrichment Analysis [GSEA]), we identified significantly altered genes in HSPA9 knock-
down cells, including upregulation of TP53-induced genes (shLUC versus sh433,
FWER = 0.02) (Fig 1D and S3 Table).[19,21]
We used several methods to explore the relationship between HSPA9 and TP53 levels.
We observed that TP53 mRNA levels were increased following knockdown of HSPA9 after 7
days in erythroid culture conditions (S1B Fig). We also confirmed an increase in TP53 pro-
tein levels in sh433 and sh960 transduced cells by Western blotting (Fig 1A). Finally, we
used intracellular flow cytometry to determine whether TP53 induction was restricted to
specific subsets of CD34+ derived erythroid cells. We observed that sh960 significantly
enhanced intracellular TP53 levels compared to shGFP, regardless of CD71 expression
(p<0.05) (S2 Fig). These results suggest that knockdown of HSPA9 increases TP53 tran-
scription and translation. Next, we used a luciferase reporter assay to measure the func-
tional activity of TP53. Four days after transduction of CD34+ cells with shRNAs (using
shGFP as a control), TP53 luciferase reporter and renilla plasmids were co-electroporated
into cells and the luciferase and renilla activity were measured 48 hours after electropora-
tion. The luciferase/renilla ratio was significantly higher in sh960 transduced cells com-
pared to shGFP control (sh960 versus shGFP, p<0.05; sh433 versus sh960, p = 0.06, Fig 1E).
Collectively, the data indicate that knockdown of HSPA9 increases TP53 activity in CD34
+ cells.
Knockdown of HSPA9 increases the expression of TP53 target genes
p21 and BAX in CD34+ cells
p21 (CDKN1A), a cell cycle regulator, and BAX, a pro-apoptotic gene, were two of the high-
est expressed TP53-target genes in our erythroid culture gene chip analysis, suggesting that
they may contribute to the observed phenotype. We confirmed an increase in p21 and BAX
protein (Fig 2A) and mRNA levels (S1C and S1D Fig respectively) in HSPA9 knockdown
cells. Known p21-repressed genes were also significantly decreased in HSPA9 knockdown
cells (shGFP versus sh433, FWER p = 0.04) (Fig 2B), further implicating TP53 and p21 as
potential mediators of the cell cycle changes previously observed in HSPA9 knockdown
cells.[10]
HSPA9 interacts with TP53 in CD34+ cells and HSPA9 knockdown
increases nuclear TP53 levels
In order to further elucidate the relationship between TP53 and HSPA9, we performed immu-
noprecipitation (IP) of TP53 in untransduced CD34+ cells. We observed that HSPA9 is
detected in the eluate following immunoprecipitation with a TP53 antibody. The IgG immu-
noprecipitation was used as the negative control, and neither protein was detected in this
immunoprecipated control complex (Fig 3A). These results suggest a direct or indirect interac-
tion between HSPA9 and TP53 in CD34+ cells. To further study the mechanism of knock-
down of HSPA9 in regulating TP53 expression and activity, we isolated the cytosolic and
nuclear fractions after knockdown of HSPA9 in CD34+ cells. Western blotting showed that
knockdown of HSPA9 decreased TP53 levels in the cytoplasm and increased TP53 levels in the
nucleus (Fig 3B), suggesting knockdown of HSPA9 leads to an increase in TP53 nuclear locali-
zation in CD34+ cells. The increase in nuclear TP53 following HSPA9 knockdown was also
observed by immunofluorescence (S3 Fig)
HSPA9 knockdown induces apoptosis
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Reduction of TP53 inhibits the apoptosis induced by HSPA9 knockdown
We have shown that knockdown of HSPA9 can increase TP53 levels and induce apoptosis.
Next, we asked whether reducing the levels of TP53 could inhibit the apoptosis induced by
knockdown of HSPA9 in CD34+ cells. We tested 5 shRNAs targeting TP53 using a lentiviral
construct containing a hygromycin resistance gene. After comparing knockdown achieved by
each of the 5 constructs, we proceeded with shTP53#3 and shTP53#4 which were able to
decrease TP53 levels by about 80% and 50%, respectively, compared to control shGFP (Fig
4A). We next co-transduced lentiviruses containing shRNA targeting HSPA9 and TP53 into
CD34+ cells, using double antibiotic selection with puromycin and hygromycin, respectively.
Consistent with shRNAs targeting HSPA9 alone, cells transduced with shGFP-hygromycin
and sh433-puromycin or sh960-puromycin increased the percentage of Annexin V positive
cells compared to shGFP-puromycin. The apoptosis following HSPA9 knockdown compared
Fig 2. Knockdown of HSPA9 increases expression of the TP53 target genes p21 and BAX in CD34
+ cells. (A) Representative immunoblot of p21 and BAX following knockdown of HSPA9 in CD34+ cells. (B)
Gene Set Enrichment Analysis (GSEA) enrichment score plot for 13 annotated p21-inhibited genes. Individual
genes in the gene set are represented by a black vertical bar in the middle of the plot.
doi:10.1371/journal.pone.0170470.g002
HSPA9 knockdown induces apoptosis
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to shGFP was significantly decreased following simultaneous knockdown of TP53 with
shTP53#3 and shTP53 #4 (p<0.05) (Fig 4B, S4 Fig).
Pharmacologic inhibition of HSPA9 induces apoptosis in CD34+ cells
Next, we studied the effects of pharmacologic inhibition of HSPA9 on cell growth, apoptosis,
and TP53 levels in CD34+ cells using MKT-077, an inhibitor of HSP70 protein family mem-
bers including HSPA9.[22] Following 5 days of MKT-077 treatment of CD34+ cells, HSPA9
expression was reduced in a dose-dependent manner (Fig 5A). MKT-077 also inhibits CD34
+ cell growth in a dose-dependent manner (Fig 5B) and increased apoptosis by day 5 (Fig 5C).
TP53 protein levels (S5 Fig) and the expression of the TP53 target genes p21 and BAX were
also increased following treatment with MKT-077 (Fig 5A).
Cells with reduced HSPA9 are sensitive to MKT-077 treatment
Haploinsufficiency of some genes can sensitize cells to further reductions in their level of
expression. This concept has been proposed as a therapeutic approach to kill cancer cells har-
boring genes that are sensitive to complete loss of expression, referred to as CYCLOPS genes.
[23] HSPA9 is reduced by 50% in del(5q)-associated MDS cells, consistent with haploinsuffi-
cient levels.[4] We tested whether MDS samples with del(5q) spanning the HSPA9 gene
maybe more sensitive to further HSPA9 reduction than MDS samples without del(5q) using
MKT-077. While MKT-077 induced apoptosis in all BM cells in a dose-dependent manner, we
observed that 0.5 μM of MKT-077 induced a higher percentage of apoptosis in del(5q)-
Fig 3. HSPA9 and TP53 interact in CD34+ cells and HSPA9 knockdown increases nuclear TP53 levels. (A)
Representative immunoblots of TP53 and HSPA9 following immunoprecipitation with anti-TP53 or an IgG control. (B)
Representative immunoblots of TP53 from the cytoplasmic and nuclear fractions of cell lysates following knockdown
of HSPA9 in CD34+ cells grown in erythroid culture conditions for 5 days.
doi:10.1371/journal.pone.0170470.g003
HSPA9 knockdown induces apoptosis
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associated MDS bone marrow cells (i.e., cells with reduced HSPA9) compared to non-del(5q)
MDS cells and normal cells [non-del(5q) versus normal, p<0.01; del(5q) versus non-del(5q),
p<0.001; del(5q) versus normal, p<0.01; Fig 6A, S4B–S4D Fig]. The increased apoptosis
induced by MKT-077 in del(5q) MDS cells was associated with reduced HSPA9 levels com-
pared to vehicle-treated cells (S6 Fig).
Fig 4. Reduction of TP53 inhibits apoptosis induced by HSPA9 knockdown. (A) Immunoblot of TP53 following knockdown
of TP53 by shRNAs in CD34+ cells grown in erythroid culture conditions for 4 days. (B) CD34+ cells grown in erythroid culture
conditions were co-transduced with lentiviral constructs carrying an shRNA targeting TP53 with a hygromycin resistance gene
(e.g., shGFP, shTP53-3, or shTP53-4) and an shRNA targeting HSPA9 with a puromycin resistance gene (shGFP, sh433, or
sh960). Cells were grown in the presence of both hygromycin and puromycin and the fold change in the percentage of Annexin V
+ cells was measured by flow cytometry and normalized to the shGFP-hygromycin/shGFP-puromycin transduced cells (n = 3
technical replicates, representative of 2 independent experiments). *p<0.05, **p<0.01,***p<0.001.
doi:10.1371/journal.pone.0170470.g004
HSPA9 knockdown induces apoptosis
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Discussion
The present study addresses the effects of HSPA9 expression levels on apoptosis in hematopoi-
etic cells. Del(5q) MDS bone marrow samples display increased apoptosis associated with an
induction of TP53 in erythroid cells and upregulation of TP53 target gene expression.[12,13]
Two commonly deleted regions (CDRs) exist at chromosome 5q33.1 (distal) and 5q31.2 (prox-
imal) in patients with del(5q)-associated myeloid diseases. In this report, we observed that
knockdown of HSPA9, a gene on the proximal chromosome 5 CDR, increased TP53 levels and
functional activity, resulting in apoptosis in primary human hematopoietic progenitor cells.
Knockdown of HSPA9 resulted in a dose-dependent increase in TP53 levels and transactiva-
tion of down-stream target genes, including pro-apoptotic BAX, and subsequently increased
apoptosis. Apoptosis in knockdown cells was rescued by reducing TP53 levels, supporting that
apoptosis induced by HSPA9 knockdown is TP53-dependent. Our data also suggest that
reduction of HSPA9 below haploinsufficient levels is poorly tolerated by cells, potentially pro-
viding a genetic vulnerability that could be leveraged by further reducing HSPA9 levels in del
Fig 5. HSPA9 inhibitor MKT-077 reduces cell growth, induces apoptosis, and increases p21 and BAX expression in CD34
+ cells. (A) Immunoblot of HSPA9, p21, BAX and TP53 following MKT-077 treatment of CD34+ cells grown in erythroid culture
conditions for 5 days. (B) CD34+ cells were seeded at equal concentrations in erythroid culture conditions, and the total number of
cells was counted daily in the presence of MKT-077. The fold change in cell counts was calculated relative to the number of cells on
day 1 (n = 3) (0.5 μM versus control, p<0.001; 2 μM versus control, p<0.001). (C) Quantification of Annexin V+ cells (a surrogate for
apoptosis) following treatment of CD34+ cells with various concentrations of MKT-077 for 5 days (n = 3). ***p<0.001.
doi:10.1371/journal.pone.0170470.g005
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(5q) cells. We show that del(5q)-associated MDS cells tend to be more sensitive to pharmaco-
logic inhibition of HSPA9 compared to non-del(5q) cells. Collectively, the data suggest that
haploinsufficiency of HSPA9 on del(5q) induces TP53 and may contribute to the accelerated
apoptosis seen in del(5q)-associated MDS.
Haploinsufficiency of RPS14, a gene on the distal chromosome 5 CDR, has been shown to
induce apoptosis in primary hematopoietic cells. Haploinsufficiency of RPS14 results in
increased TP53 levels in primary human erythroid cells and bone marrow cells from mice
lacking one copy of Rps14 alone [24], or in combination with 7 other contiguous genes.[12,25]
Genetic deletion of Tp53 in mice haploinsufficient for Rps14 reversed many of the
Fig 6. Del(5q)-associated MDS bone marrow cells are sensitive to MKT-077 treatment. (A) Bone marrow (BM) cells from a healthy
donor (normal BM) and MDS patients without and with del(5q) (n = 1 each) were treated with various concentrations of MKT-077 for 4
days. The fold change in the percentage of Annexin V+ cells was measured by flow cytometry and normalized to 0 μM of MKT-077 (n = 3,
technical replicates). (B) Model of the mechanism of TP53 activation following HSPA9 knockdown. HSPA9 interacts with TP53 in the
cytoplasm. HSPA9 reduction leads to the release of TP53 from the HSPA9-TP53 cytoplasmic complex. Translocation of TP53 into the
nucleus activates downstream target genes BAX and p21. *p<0.05, **p<0.01, ***p<0.001.
doi:10.1371/journal.pone.0170470.g006
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hematopoietic deficits induced by Rps14 deletion, suggesting that elevated TP53 levels are
responsible for many of the phenotypic abnormalities induced by RPS14 haploinsufficiency.
[24,25] How del(5q) hematopoietic cells gain clonal dominance in MDS when haploinsuffi-
ciency of several genes (e.g., RPS14 and HSPA9) cause increased apoptosis is an active area of
research. There is evidence that haploinsufficiency of the casein kinase 1A1 gene (Csnk1a1) in
mice, located on the chromosome 5 distal CDR in humans, induces hematopoietic stem cell
expansion and a competitive repopulation advantage.[26] Therefore, some del(5q) genes may
induce apoptosis while others contribute to clonal dominance. In addition, many groups have
shown that mutations or deletions of TP53 are significantly associated with loss of chromo-
some 5 or del(5q) in myeloid malignancies.[27–31] It may be that mutation, deletion, or mod-
ulation of TP53 is required for low-risk MDS cells with increased apoptosis to progress to
high-risk MDS or secondary AML. Indeed, TP53 mutant cells can be found at low levels in
patients with low-risk del(5q)-associated MDS and mutations are associated with evolution to
acute myeloid leukemia.[32] Collectively, the data suggest that the cooperation of multiple del
(5q) genes, and genes on other chromosomes (e.g., TP53), cooperate to induce the phenotypes
observed in patients with MDS.
HSPA9 is a chaperone for many proteins. We show that HSPA9 and TP53 interact directly
or indirectly in primary human hematopoietic cells, similar to that observed in non-hemato-
poietic cells.[15] Knockdown of HSPA9 leads to an increase in TP53 in the nucleus, resulting
in transactivation of TP53 target genes and increased apoptosis (Fig 6B). Increased apoptosis
in hematopoietic cells has been observed in various HSPA9 knockdown models, including pri-
mary human and mouse hematopoietic cells.[10,16] The known function of HSPA9 to protect
cells from a variety of stresses may be partially mediated through its regulation of TP53, and
haploinsufficiency may ultimately limit a cell’s ability to appropriately regulate stress states,
including MDS. The level of HSPA9 expression and timing of deletion may be important for
these phenotypes, as we have previously reported that constitutive heterozygous deletion of
Hspa9 in mice does not result in cytopenias.[11] This suggests that compensation for a consti-
tutive deletion of Hspa9 may occur during mouse development. HSPA1A, another Hsp70 fam-
ily member, has been shown to regulate erythropoiesis by preventing active caspase-3 from
cleaving GATA1 in the nucleus and inducing apoptosis.[33] Expression of a nucleus-targeted
HSPA1A in MDS samples rescued erythroid cell differentiation, implicating this Hsp70 family
member in MDS pathogenesis.[34]
The activation of wild-type TP53 and induction of apoptosis by haploinsufficiency of del
(5q) genes, including RPS14 and HSPA9, may contribute to bone marrow failure and ineffec-
tive hematopoiesis in MDS.[35] Haploinsufficiency of genes may also create a genetic vulnera-
bility that could be used to selectively kill del(5q)-containing cells. While we observed that
~50% reduction of HSPA9 increases apoptosis and reduces cell growth, >50% knockdown of
HSPA9 severely limits hematopoietic cell growth in vitro and in vivo.[9,10] In addition, com-
plete loss of Hspa9 in mice is early embryonic lethal, suggesting that reducing HSPA9 levels
below 50% may be lethal to cells.[11] Consistent with complete loss of Hspa9 being lethal,
HSPA9 has recently been identified as an essential gene in human cells.[36,37] Inherited vari-
ants in HSPA9 have also been associated with congenital sideroblastic anemia with data sug-
gesting >50% reduction is required to cause this phenotype.[35] In cancer, the paradigm of
modulating gene dosage as a therapeutic approach was experimentally established several
years ago with the identification of CYCLOPS (copy number alterations yielding cancer liabili-
ties owing to partial loss) genes.[23] To test whether reduction in HSPA9 below haploinsuffi-
cient levels cells could further increase apoptosis, we used MKT-077, a rhodacyanine dye that
inhibits the activity of HSP70 family members, to treat HSPA9 knockdown cells and del(5q)-
associated MDS samples.[22,38,39] While MKT-077 likely has a broad range of targets, we
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showed using this proof-of-concept approach that cells with reduced HSPA9 tended to be
more sensitive to apoptosis induction following MKT-077 exposure compared to control cells.
The successful paradigm of targeting a CYCLOPS gene on del(5q) has been elegantly shown to
be the mechanism underlying the sensitivity of del(5q) cells to lenalidomide treatment.[23]
Del(5q) cells are more sensitive to lenalidomide than normal cells because the drug induces
degradation of CSNK1A1, a gene that is expressed at haploinsufficient levels in del(5q) cells
compared to normal cells.[40]
The simultaneous loss of multiple genes on del(5q) likely contributes to the complex pheno-
types observed in MDS.[26,35,41–49] Some genes contribute to increased apoptosis, thrombo-
cytopenia, clonal dominance, B cell defects, and genetic susceptibility to treatments. The co-
occurrence of TP53 mutations suggests a specific advantage, and possibly dependence, of these
two genetic mutations in MDS cells. Future studies designed to eradicate TP53 mutant cells is
a high priority to improve outcomes in patients with MDS.
Supporting information
S1 Fig. mRNA expression in CD34+ cells following HSPA9 knockdown. (A) Fold change in
HSPA9 mRNA expression in CD34+ cells grown in erythroid culture conditions normalized
to shGFP control cells (n = 3). (B) Fold change in TP53 mRNA expression in CD34+ cells
grown in erythroid culture conditions normalized to shGFP control cells (n = 3). (C) Fold
change in p21 mRNA expression in CD34+ cells grown in erythroid culture conditions nor-
malized to shGFP control cells (n = 3). (D) Fold change in BAX mRNA expression in CD34
+ cells grown in erythroid culture conditions normalized to shGFP control cells (n = 3).
(TIF)
S2 Fig. Measurement of TP53 levels in CD34+ cells following knockdown of HSPA9. (A)
(left panel) Representative histogram of intracellular TP53 levels measured by flow cytometry
in bulk CD34+ cells grown in erythroid culture conditions following knockdown of HSPA9.
(right panel) Mean fluorescence intensity (MFI) of TP53 following knockdown of HSPA9
(n = 3). (B) MFI of TP53 in CD71+ or CD71- cells following knockdown of HSPA9 in CD34
+ cells, grown in erythroid culture conditions (n = 3). p<0.05.
(TIF)
S3 Fig. Immunofluorescence of TP53 in CD34+ cells following knockdown of HSPA9. Rep-
resentative images of CD34+ cells transduced with lentiviral shRNA and cultured for 5 days.
Antibody control represents CD34+ cells transduced with sh960 targeting HSPA9 and pro-
cessed only with the secondary antibody, but not the primary antibody.
(TIF)
S4 Fig. Measurement of apoptosis in cells transduced by various shRNAs or treated with
MKT-077. (A) Non-normalized data presented in Fig 4B. CD34+ cells grown in erythroid cul-
ture conditions were co-transduced with lentiviral constructs carrying an shRNA targeting
TP53 with a hygromycin resistance gene (e.g., shGFP, shTP53-3, or shTP53-4) and an shRNA
targeting HSPA9 with a puromycin resistance gene (shGFP, sh433, or sh960). Cells were
grown in the presence of both hygromycin and puromycin and the fold change in the percent-
age of Annexin V+ cells was measured by flow cytometry (n = 3 technical replicates). (B).
Non-normalized data presented in Fig 6A. Bone marrow (BM) cells from a healthy donor
(normal BM) and MDS patients without and with del(5q) (n = 1 each) were treated with vari-
ous concentrations of MKT-077 for 4 days. The percentage of Annexin V+ cells was measured
by flow cytometry (n = 3, technical replicates). (C) Bone marrow (BM) cells from a healthy
donor (normal BM) and MDS patients without and with del(5q) (n = 1 each) were treated
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with various concentrations of MKT-077 for 4 days (non-overlapping samples with Fig 6A).
The percentage of Annexin V+ cells was measured by flow cytometry (n = 3, technical repli-
cates). (D) Non-normalized data presented above in panel C. The percentage of Annexin V
+ cells was measured by flow cytometry (n = 3, technical replicates). p<0.05, p<0.01,
p<0.001.
(TIF)
S5 Fig. MKT-077 treatment increases TP53 levels in CD34+ cells following knockdown of
HSPA9. (A) Mean fluorescence intensity (MFI) of TP53 following treatment with various
doses of MKT-077 (n = 3 technical replicates, representative of 2 independent experiments).
p<0.001.
(TIF)
S6 Fig. HSPA9 levels are reduced in MDS cells following treatment with MKT-077. Bone
marrow (BM) cells from a MDS patient with del(5q) were treated with various concentrations
of MKT-077 for 4 days. Immunoblot of HSPA9 and beta-actin protein is shown.
(TIF)
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S2 Table. Quantification of Western blot images by densitometry.
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S3 Table. TP53-induced and p21-inhibited gene lists used for GSEA analysis.
(DOCX)
Acknowledgments
We thank the Alvin J. Siteman Cancer Center at Washington University School of Medicine
and Barnes-Jewish Hospital in St. Louis, MO., for the use of the Siteman Flow Cytometry
Core, which provided flow cytometry service. Additional technical assistance was provided by
the Hope Center Viral Vectors Core. We thank Dr. Alexander Zaika for the PG13 TP53 lucif-
erase reporter plasmid. We thank Fred Hutchinson Cancer Research Center for providing
human CD34+ cells in our studies.
Author contributions
Conceptualization: MW.
Data curation: TL CS MN MW.
Formal analysis: TL JS MW.
Funding acquisition: MW.
Investigation: TL KK CS SK MN MW.




Validation: TL KK CS SK MN MW.
HSPA9 knockdown induces apoptosis
PLOS ONE | DOI:10.1371/journal.pone.0170470 February 8, 2017 15 / 18
Visualization: TL MN MW.
Writing – original draft: TL MW.
Writing – review & editing: TL KK MW.
References
1. Boultwood J, Fidler C, Strickson AJ, Watkins F, Gama S, Kearney L, et al. (2002) Narrowing and geno-
mic annotation of the commonly deleted region of the 5q− syndrome. Blood 99: 4638–4641. PMID:
12036901
2. Zhao N, Stoffel A, Wang PW, Eisenbart JD, Espinosa R III, Larson RA, et al. (1997) Molecular delinea-
tion of the smallest commonly deleted region of chromosome 5 in malignant myeloid diseases to 1–1.5
Mb and preparation of a PAC-based physical map. Proceedings of the National Academy of Sciences
of the United States of America (PNAS) 94: 6948–6953.
3. Jerez A, Gondek LP, Jankowska AM, Makishima H, Przychodzen B, Tiu RV, et al. (2012) Topography,
clinical, and genomic correlates of 5q myeloid malignancies revisited. Journal of Clincial Oncology 30:
1343–1349.
4. Graubert TA, Payton MA, Shao J, Walgren RA, Monahan RS, Frater JL, et al. (2009) Integrated Geno-
mic Analysis Implicates Haploinsufficiency of Multiple Chromosome 5q31.2 Genes in De Novo Myelo-
dysplastic Syndromes Pathogenesis. PLoS One 4: e4583. doi: 10.1371/journal.pone.0004583 PMID:
19240791
5. Wadhwa R, Yaguchi T, Hasan MK, Mitsui Y, Reddel RR, Kaul SC (2002) Hsp70 family member, mot-2/
mthsp70/GRP75, binds to the cytoplasmic sequestration domain of the p53 protein. Experimental Cell
Research 274: 246–253. doi: 10.1006/excr.2002.5468 PMID: 11900485
6. Kaul SC, Taira K, Pereira-Smith OM, Wadhwa R (2002) Mortalin: present and prospective. Experimen-
tal Gerontology 37: 1157–1164. PMID: 12470827
7. Chen TH, Kambal A, Krysiak K, Walshauser MA, Raju G, Tibbitts JF, et al. (2011) Knockdown of
Hspa9, a del(5q31.2) gene, results in a decrease in hematopoietic progenitors in mice. Blood 117:
1530–1539. doi: 10.1182/blood-2010-06-293167 PMID: 21123823
8. Craven SE, French D, Ye W, de Sauvage F, Rosenthal A (2005) Loss of Hspa9b in zebrafish recapitu-
lates the ineffective hematopoiesis of the myelodysplastic syndrome. Blood 105: 3528–3534. doi: 10.
1182/blood-2004-03-1089 PMID: 15650063
9. Tai-Nagara I, Matsuoka S, Ariga H, Suda T (2014) Mortalin and DJ-1 coordinately regulate hematopoi-
etic stem cell function through the control of oxidative stress. Blood 123: 41–50. doi: 10.1182/blood-
2013-06-508333 PMID: 24243970
10. Chen TH-P, Kambal AK, Krysiak K, Walshauser MA, Raju G, Tibbitts JF, et al. (2011) Knockdown of
Hspa9, a del(5q31.2) gene, results in a decrease in hematopoietic progenitors in mice. Blood 117:
1530–1539. doi: 10.1182/blood-2010-06-293167 PMID: 21123823
11. Krysiak K, Tibbitts JF, Shao J, Liu T, Ndonwi M, Walter MJ (2015) Reduced levels of Hspa9 attenuates
Stat5 activation in mouse B-cells. Experimental Hematology 43: 319–330. doi: 10.1016/j.exphem.
2014.12.005 PMID: 25550197
12. Dutt S, Narla A, Lin K, Mullally A, Abayasekara N, Megerdichian C, et al. (2011) Haploinsufficiency for
ribosomal protein genes causes selective activation of p53 in human erythroid progenitor cells. Blood
117: 2567–2576. doi: 10.1182/blood-2010-07-295238 PMID: 21068437
13. Pellagatti A, Marafioti T, Paterson JC, Barlow JL, Drynan LF, Giagounidis A, et al. (2010) Induction of
p53 and up-regulation of the p53 pathway in the human 5q- syndrome. Blood 115: 2721–2723. doi: 10.
1182/blood-2009-12-259705 PMID: 20360478
14. Gestl EE, Bo¨ttger SA (2012) Cytoplasmic sequestration of the tumor suppressor p53 by a heat shock
protein 70 family member, mortalin, in human colorectal adenocarcinoma cell lines. Biochemical and
Biophysical Research Communications 432: 411–416.
15. Kaul SC, Aida S, Yaguchi T, Kaur K, Wadhwa R (2005) Activation of wild type p53 function by its morta-
lin-binding, cytoplasmically localizing carboxyl terminus peptides. The Journal of Biological Chemistry
280: 39373–39379. doi: 10.1074/jbc.M500022200 PMID: 16176931
16. Lu W-J, Lee NP, Kaul SC, Lan F, Poon RTP, Wadhwa R, et al. Induction of mutant p53-dependent apo-
ptosis in human hepatocellular carcinoma by targeting stress protein mortalin. International Journal of
Cancer 129: 1806–1814. doi: 10.1002/ijc.25857 PMID: 21165951
17. Gagnon KT, Li LL, Janowski BA, Corey DR (2014) Analysis of nuclear RNA interference in human cells
by subcellular fractionation and Argonaute loading. Nature Protocols 9: 2045–2060. doi: 10.1038/nprot.
2014.135 PMID: 25079428
HSPA9 knockdown induces apoptosis
PLOS ONE | DOI:10.1371/journal.pone.0170470 February 8, 2017 16 / 18
18. Zaika A, Irwin M, Sansome C, Moll UM (2001) Oncogenes induce and activate endogenous p73 protein.
Journal of Biological Chemistry 276: 11310–11316. doi: 10.1074/jbc.M005737200 PMID: 11115495
19. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, et al. (2005) Gene set
enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles.
Proceedings of the National Academy of Sciences of the United States of America (PNAS) 102:
15545–15550.
20. Sola´ S, Xavier JM, Santos DM, Aranha MM, Morgado AL, Jepsen K, et al. (2011) p53 interaction with
JMJD3 results in its nuclear distribution during mouse neural stem cell differentiation. PLoS One 6:
e18421. doi: 10.1371/journal.pone.0018421 PMID: 21483786
21. Tusher VG, Tibshirani R, Chu G (2001) Significance analysis of microarrays applied to the ionizing radi-
ation response. Proceedings of the National Academy of Sciences of the United States of America
(PNAS) 98: 5116–5121.
22. Wadhwa R, Sugihara T, Yoshida A, Nomura H, Reddel RR, Simpson R, et al. (2000) Selective toxicity
of MKT-077 to cancer cells is mediated by its binding to the hsp70 family protein mot-2 and reactivation
of p53 function. Cancer Research 60: 6818–6821. PMID: 11156371
23. Nijhawan D, Zack TI, Ren Y, Strickland MR, Lamothe R, Schumacher SE, et al. (2012) Cancer vulnera-
bilities unveiled by genomic loss. Cell 150: 842–854. doi: 10.1016/j.cell.2012.07.023 PMID: 22901813
24. Schneider RK, Schenone M, Ferreira MV, Kramann R, Joyce CE, Hartigan C, et al. (2016) Rps14 hap-
loinsufficiency causes a block in erythroid differentiation mediated by S100A8 and S100A9. Nature
Medicine 22: 288–297. doi: 10.1038/nm.4047 PMID: 26878232
25. Barlow JL, Drynan LF, Hewett DR, Holmes LR, Lorenzo-Abalde S, Lane AL, et al. (2010) A p53-depen-
dent mechanism underlies macrocytic anemia in a mouse model of human 5q- syndrome. Nature Medi-
cine 16: 59–66. doi: 10.1038/nm.2063 PMID: 19966810
26. Schneider RK, Ademà V, Heck D, Ja¨rås M, Mallo M, Lord AM, et al. (2014) Role of casein kinase 1A1 in
the biology and targeted therapy of del(5q) MDS. Cancer Cell 26: 509–520. doi: 10.1016/j.ccr.2014.08.
001 PMID: 25242043
27. Bejar R, Stevenson K, Abdel-Wahab O, Galili N, Nilsson B, Garcia-Manero G, et al. (2011) Clinical
effect of point mutations in myelodysplastic syndromes. The New England Journal of Medicine 364:
2496–2506. doi: 10.1056/NEJMoa1013343 PMID: 21714648
28. Bejar R, Stevenson KE, Caughey B, Lindsley RC, Mar BG, Stojanov P, et al. (2014) Somatic mutations
predict poor outcome in patients with myelodysplastic syndrome after hematopoietic stem-cell trans-
plantation. Journal of Clincial Oncology 32: 2691–2698.
29. Papaemmanuil E, Gerstung M, Malcovati L, Tauro S, Gundem G, Van Loo P, et al. (2013) Clinical and
biological implications of driver mutations in myelodysplastic syndromes. Blood 122: 3616–3627. doi:
10.1182/blood-2013-08-518886 PMID: 24030381
30. Walter M, Shen D, Shao J, Ding L, White B, Kandoth C, et al. (2013) Clonal diversity of recurrently
mutated genes in myelodysplastic syndromes. Leukemia 27: 1275–1282. doi: 10.1038/leu.2013.58
PMID: 23443460
31. Haferlach T, Nagata Y, Grossmann V, Okuno Y, Bacher U, Nagae G, et al. (2014) Landscape of genetic
lesions in 944 patients with myelodysplastic syndromes. Leukemia 28: 241–247. doi: 10.1038/leu.
2013.336 PMID: 24220272
32. Ja¨dersten M, Saft L, Smith A, Kulasekararaj A, Pomplun S, Go¨hring G, et al. (2011) TP53 mutations in
low-risk myelodysplastic syndromes with del(5q) predict disease progression. Journal of Clincial Oncol-
ogy 29: 1971–1979.
33. Ribeil JA, Zermati Y, Vandekerckhove J, Cathelin S, Kersual J, Dussiot M, et al. (2007) Hsp70 regulates
erythropoiesis by preventing caspase-3-mediated cleavage of GATA-1. Nature 445: 102–105. doi: 10.
1038/nature05378 PMID: 17167422
34. Frisan E, Vandekerckhove J, de Thonel A, Pierre-Eugene C, Sternberg A, Arlet JB, et al. (2012) Defec-
tive nuclear localization of Hsp70 is associated with dyserythropoiesis and GATA-1 cleavage in myelo-
dysplastic syndromes. Blood 119: 1532–1542. doi: 10.1182/blood-2011-03-343475 PMID: 22160620
35. Schmitz-Abe K, Ciesielski SJ, Schmidt PJ, Campagna DR, Rahimov F, Schilke BA, et al. (2015) Con-
genital sideroblastic anemia due to mutations in the mitochondrial HSP70 homologue HSPA9. Blood
126: 2734–2738. doi: 10.1182/blood-2015-09-659854 PMID: 26491070
36. Blomen VA, Ma´jek P, Jae LT, Bigenzahn JW, Nieuwenhuis J, Staring J, et al. (2015) Gene essentiality
and synthetic lethality in haploid human cells. Science 350: 1092–1096. doi: 10.1126/science.aac7557
PMID: 26472760
37. Wang T, Birsoy K, Hughes NW, Krupczak KM, Post Y, Wei JJ, et al. (2015) Identification and characteri-
zation of essential genes in the human genome. Science 350: 1096–1101. doi: 10.1126/science.
aac7041 PMID: 26472758
HSPA9 knockdown induces apoptosis
PLOS ONE | DOI:10.1371/journal.pone.0170470 February 8, 2017 17 / 18
38. Koya K, Li Y, Wang H, Ukai T, Tatsuta N, Kawakami M, et al. (1996) MKT-077, a novel rhodacyanine
dye in clinical trials, exhibits anticarcinoma activity in preclinical studies based on selective mitochon-
drial accumulation. Cancer Research 56: 538–543. PMID: 8564968
39. Li X, Srinivasan SR, Connarn J, Ahmad A, Young ZT, Kabza AM, et al. (2013) Analogs of the allosteric
heat shock protein 70 (Hsp70) inhibitor, MKT-077, as anti-cancer agents. ACS Medicinal Chemistry Let-
ters 4: 1042–1047.
40. Kro¨nke J, Fink EC, Hollenbach PW, MacBeth KJ, Hurst SN, Udeshi ND, et al. (2015) Lenalidomide
induces ubiquitination and degradation of CK1α in del(5q) MDS. Nature 523: 183–188. doi: 10.1038/
nature14610 PMID: 26131937
41. Liu TX, Becker MW, Jelinek J, Wu W-S, Deng M, Mikhalkevich N, et al. (2006) Chromosome 5q deletion
and epigenetic suppression of the gene encoding alpha-catenin (CTNNA1) in myeloid cell transforma-
tion. Nature Medicine 13: 78–83. doi: 10.1038/nm1512 PMID: 17159988
42. Varney ME, Niederkorn M, Konno H, Matsumura T, Gohda J, Yoshida N, et al. (2015) Loss of Tifab, a
del(5q) MDS gene, alters hematopoiesis through derepression of Toll-like receptor-TRAF6 signaling.
Journal of Experimental Medicine 212: 1967–1985. doi: 10.1084/jem.20141898 PMID: 26458771
43. Joslin JM, Fernald AA, Tennant TR, Davis EM, Kogan SC, Anastasi J, et al. (2007) Haploinsufficiency
of EGR1, a candidate gene in the del(5q), leads to the development of myeloid disorders. Blood 110:
719–726. doi: 10.1182/blood-2007-01-068809 PMID: 17420284
44. Stoddart A, Fernald AA, Wang J, Davis EM, Karrison T, Anastasi J, et al. (2014) Haploinsufficiency of
del(5q) genes, Egr1 and Apc, cooperate with Tp53 loss to induce acute myeloid leukemia in mice.
Blood 123: 1069–1078. doi: 10.1182/blood-2013-07-517953 PMID: 24381225
45. Starczynowski DT, Kuchenbauer F, Argiropoulos B, Sung S, Morin R, Muranyi A, et al. (2010) Identifica-
tion of miR-145 and miR-146a as mediators of the 5q- syndrome phenotype. Nature Medicine 16: 49–
58. doi: 10.1038/nm.2054 PMID: 19898489
46. Young DJ, Stoddart A, Nakitandwe J, Chen S-C, Qian Z, Downing JR, et al. (2014) Knockdown of
Hnrnpa0, a del(5q) gene, alters myeloid cell fate in murine cells through regulation of AU-rich tran-
scripts. Haematologica 99: 1032–1040. doi: 10.3324/haematol.2013.098657 PMID: 24532040
47. Sportoletti P, Grisendi S, Majid SM, Cheng K, Clohessy JG, Viale A, et al. (2008) Npm1 is a haploinsuffi-
cient suppressor of myeloid and lymphoid malignancies in the mouse. Blood 111: 3859–3862. doi: 10.
1182/blood-2007-06-098251 PMID: 18212245
48. Wang J, Fernald AA, Anastasi J, Le Beau MM, Qian Z (2010) Haploinsufficiency of Apc leads to ineffec-
tive hematopoiesis. Blood 115: 3481–3488. doi: 10.1182/blood-2009-11-251835 PMID: 20065296
49. Lane SW, Sykes SM, Al-Shahrour F, Shterental S, Paktinat M, Lo Celso C, et al. (2010) The Apc(min)
mouse has altered hematopoietic stem cell function and provides a model for MPD/MDS. Blood 15:
3489–3497.
HSPA9 knockdown induces apoptosis
PLOS ONE | DOI:10.1371/journal.pone.0170470 February 8, 2017 18 / 18
